Paliperidone Palmitate Therapeutic Injection Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1791243
리서치사:Lucintel
발행일:2025년 08월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 팔리페리돈 팔미테이트 치료용 주사 시장 전망은 일반 병원 시장과 전문 병원 시장에서의 기회가 있어 유망시되고 있습니다. 세계의 팔리페리돈 팔미테이트 치료용 주사 시장은 2025-2031년 CAGR 6.3%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 세계 정신 분열증 환자 증가, 장시간 작용 주사제에 대한 선호도 증가, 환자 규정 준수 치료에 대한 수요 증가입니다.
Lucintel사의 예측에서는 유형별로는 3개월마다 투여 제제가 예측 기간 중에 높은 성장을 이룰 전망입니다.
용도별로는 전문 병원이 높은 성장이 예상됩니다.
지역별로는 아시아태평양이 예측 기간 가장 높은 성장이 예상됩니다.
150페이지 이상의 종합적인 보고서를 통해 비즈니스 의사 결정에 도움이 되는 귀중한 인사이트를 얻을 수 있습니다.
팔리페리돈 팔미테이트 치료용 주사 시장의 새로운 동향
팔리페리돈 팔미테이트 치료용 주사 시장은 현재 환자의 결과와 편의성을 향상시키고, 이 장시간 작용형 항정신병제의 적용 범위를 넓히는 것을 목적으로 한 새로운 동향을 많이 볼 수 있습니다. 이러한 추세는 정신분열증 치료에 대한 평가 증가와 약물 전달 시스템의 혁신을 보여줍니다.
초장시간 작용형 주사제 : 주요 동향의 하나는 초장시간 작용형 팔리페리돈 팔미테이트 제제(3개월 제제나 6개월 제제 등)의 개발 및 사용이며, 주사의 빈도를 줄이고, 환자의 어드히어런스를 더욱 높여, 치료 부담을 경감할 가능성이 있습니다.
정신분열증에 대한 주목 : 팔리페리돈팔미트산에스테르와 같은 장시간 작용형 주사항정신병제을, 특히 정신분열증 환자에서 치료 과정의 초기 단계에서 사용하여 장기적인 결과 및 재발 예방을 높이는 것이 중시되고 있습니다.
디지털 건강 기술과의 통합 : 새로운 동향으로는 복약 컴플라이언스 소프트웨어 및 원격 모니터링 시스템과 같은 디지털 건강 도구를 통합하고 팔리페리돈 팔미테이트 요법을 보완하고 환자 관리를 촉진하는 것입니다.
실제 세계 증거 창출 : 팔리페리돈 팔미테이트의 다양한 제형의 효능, 안전성 및 환자 보고 결과에 대한 이해를 높이기 위해 실제 임상 데이터 수집 및 분석에 점점 더 초점이 맞추어지고 있습니다.
피하 제형 개발 : 팔리페리돈 팔미테이트의 피하 제형은 근육내 주사보다 침습이 적고 간편한 투여 경로가 될 수 있으며, 현재 연구가 진행되고 있습니다.
이러한 동향은 환자에게 친절하고 편리한 치료 방법의 창출을 촉진하고, 팔리페리돈 팔미테이트 치료용 주사 시장을 일변시키고 있습니다. 초 장시간 작용 제형, 조기 치료, 디지털 건강 도입, 실제 임상 증거, 대체 투여 경로의 중요성은 정신분열증 치료에서 팔리페리돈 팔미테이트의 가치를 증가시킵니다.
팔리페리돈 팔미테이트 치료용 주사 시장의 최근 동향
팔리페리돈 팔미테이트 치료용 주사 시장 특징은 치료 효과의 극대화, 환자의 편의성 향상, 정신분열증 관리에서 임상적 유용성의 향상을 목표로 한 지속적인 시장 개척입니다. 이러한 진전은 정신분열증 환자의 삶을 개선하기 위한 지속적인 노력임을 보여줍니다.
작용 연장형 제제의 승인 획득 : 팔리페리돈 팔미테이트의 3개월 및 6개월 지속형 제제가 최근 여러 지역에서 승인되었다는 것은 주사 빈도를 최소화하고 환자의 어드레싱을 극대화하는 방향으로 큰 단계입니다.
승인 후 안전성 시험 : 현재 진행 중인 승인 후 안전성 시험은 다양한 환자 집단에서 다양한 팔리페리돈 팔미테이트 제제의 장기적인 안전성 및 내약성에 대한 중요한 발견을 제공합니다.
약물 경제 분석 : 약물경제학적 데이터의 이용가능성이 높아지고, 재발, 입원, 총 의료비의 감소라는 점에서 장시간 작용형 팔리페리돈팔미트산에스테르 주사제의 가치가 입증되고 있습니다.
보다 우수한 주사 장치 개발 : 팔리페리돈 팔미테이트를 투여하기 위한 보다 편안하고 고통이 적은 주사 장치를 개발하고 환자의 사용감을 향상시키기 위한 노력이 이루어지고 있습니다.
양극성 장애에서의 사용 검토 : 주요 적응증은 정신분열증이지만, 양극성 장애의 증상의 일부에도 사용될 수 있는 가능성이 검토되고 있으며, 용도가 확산될 수 있습니다.
이러한 큰 진보는 보다 편리하고 비용 절감으로 이어질 수 있는 치료, 장기적인 안전성에 대한 지식 증가, 보다 나은 투여 경험, 새로운 치료 용도의 검토 등, 팔리페리돈 팔미테이트 치료용 주사 시장에 큰 영향을 주고 있습니다. 보다 장시간 작용하는 제품, 안전 정보, 경제적 이익, 주사기, 보다 넓은 적응증에 중점을 두어 정신과 치료에서 팔리페리돈 팔미테이트의 지위가 강화되고 있습니다.
목차
제1장 주요 요약
제2장 시장 개요
배경 및 분류
공급망
제3장 시장 동향 및 예측 분석
거시경제 동향 및 예측
업계의 촉진요인 및 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 팔리페리돈 팔미테이트 치료용 주사 시장 : 유형별
개요
유형별 매력 분석
월1회 투여 제제 : 동향 및 예측(2019-2031년)
3개월마다 투여 제제 : 동향 및 예측(2019-2031년)
제5장 세계의 팔리페리돈 팔미테이트 치료용 주사 시장 : 용도별
개요
용도별 매력 분석
일반 병원 : 동향 및 예측(2019-2031년)
전문 병원 : 동향 및 예측(2019-2031년)
기타 : 동향 및 예측(2019-2031년)
제6장 지역 분석
개요
지역별 세계의 팔리페리돈 팔미테이트 주사제 시장
제7장 북미의 팔리페리돈 팔미테이트 치료 주사제 시장
개요
북미의 팔리페리돈 팔미테이트 치료용 주사 시장 : 유형별
북미의 팔리페리돈 팔미테이트 치료용 주사 시장 : 용도별
미국의 팔리페리돈 팔미테이트 치료용 주사 시장
멕시코의 팔리페리돈 팔미테이트 치료용 주사 시장
캐나다의 팔리페리돈 팔미테이트 치료용 주사 시장
제8장 유럽의 팔리페리돈 팔미테이트 치료용 주사 시장
개요
유럽의 팔리페리돈 팔미테이트 치료용 주사 시장 : 유형별
유럽의 팔리페리돈 팔미테이트 치료 주사제 시장 : 용도별
독일의 팔리페리돈 팔미테이트 치료용 주사 시장
프랑스의 팔리페리돈 팔미테이트 치료용 주사 시장
스페인의 팔리페리돈 팔미테이트 치료용 주사 시장
이탈리아의 팔리페리돈 팔미테이트 치료용 주사 시장
영국의 팔리페리돈 팔미테이트 치료용 주사 시장
제9장 아시아태평양의 팔리페리돈 팔미테이트 치료용 주사 시장
개요
아시아태평양 팔리페리돈 팔미테이트 치료용 주사 시장 : 유형별
아시아태평양의 팔리페리돈 팔미테이트 치료용 주사 시장 : 용도별
일본의 팔리페리돈 팔미테이트 치료용 주사 시장
인도의 팔리페리돈 팔미테이트 치료용 주사 시장
중국의 팔리페리돈 팔미테이트 치료용 주사 시장
한국의 팔리페리돈 팔미테이트 치료용 주사 시장
인도네시아의 팔리페리돈 팔미테이트 치료용 주사 시장
제10장 기타 지역의 팔리페리돈 팔미테이트 치료용 주사 시장
개요
기타 지역의 팔리페리돈 팔미테이트 치료용 주사 시장 : 유형별
기타 지역의 팔리페리돈 팔미테이트 치료용 주사 시장 : 용도별
중동의 팔리페리돈 팔미테이트 치료용 주사 시장
남미의 팔리페리돈 팔미테이트 치료용 주사 시장
아프리카의 팔리페리돈 팔미테이트 치료용 주사 시장
제11장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter's Five Forces 분석
경쟁 기업간 경쟁 관계
구매자의 협상력
공급기업의 협상력
대체품의 위협
신규 참가업체의 위협
시장 점유율 분석
제12장 기회 및 전략 분석
밸류체인 분석
성장 기회 분석
유형별 성장 기회
용도별 성장 기회
세계 팔리페리돈 팔미테이트 치료용 주사 시장의 새로운 동향
전략 분석
신제품 개발
인증 및 라이선싱
합병, 인수, 계약, 제휴 및 합작 사업
제13장 밸류체인에서 주요 기업의 기업 프로파일
경쟁 분석
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Sun Pharmaceutical
Cipla
Hikma Pharmaceuticals
Qilu Pharmaceutical
제14장 부록
List of Figures
List of Tables
Research Methodology
Disclaimer
Copyright
Abbreviations and Technical Units
About Us
Contact Us
AJY
영문 목차
영문목차
The future of the global paliperidone palmitate therapeutic injection market looks promising with opportunities in the general hospital and specialized hospital markets. The global paliperidone palmitate therapeutic injection market is expected to grow with a CAGR of 6.3% from 2025 to 2031. The major drivers for this market are the increasing cases of schizophrenia worldwide, the rising preference for long-acting injectables, and the growing demand for patient compliance treatments.
Lucintel forecasts that, within the type category, quarterly dosage form is expected to witness higher growth over the forecast period.
Within the application category, specialized hospital is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Paliperidone Palmitate Therapeutic Injection Market
The market for paliperidone palmitate therapeutic injection is today experiencing a number of emerging trends that are directed towards enhancing patient outcomes, convenience, and widening the coverage of this long-acting antipsychotic. These trends show an increasing appreciation of schizophrenia treatment and innovation in drug delivery systems.
Ultra-Long-Acting Injectable Formulations: One of the major trends is the development and utilization of ultra-long-acting paliperidone palmitate formulations (e.g., three-month and six-month), offering less frequent injection and potentially further enhancing patient adherence and alleviating the treatment burden.
First-Episode Schizophrenia Focus: There is a growing emphasis on using long-acting injectable antipsychotics, such as paliperidone palmitate, earlier in the treatment process, especially among first-episode schizophrenia patients, to enhance long-term outcomes and relapse prevention.
Integration with Digital Health Technologies: Emerging trends involve the integration of digital health tools, including medication compliance software and telemonitoring systems, to supplement paliperidone palmitate therapy and facilitate patient management.
Generation of Real-World Evidence: Increased focus is being put on gathering and analyzing real-world data to enhance the understanding of the efficacy, safety, and patient-reported outcomes of various paliperidone palmitate formulations in actual practice.
Development of Subcutaneous Formulations: Subcutaneous formulations of paliperidone palmitate are under investigation to provide a potentially less invasive and more convenient route of administration than intramuscular injection.
These trends are collectively transforming the paliperidone palmitate therapeutic injection market by motivating the creation of more patient-friendly and convenient forms of treatment. The emphasis on ultra-long-acting formulations, early treatment, digital health incorporation, real-world evidence, and alternative routes of administration is amplifying the value of paliperidone palmitate for schizophrenia treatment.
Recent Developments in the Paliperidone Palmitate Therapeutic Injection Market
The paliperidone palmitate therapeutic injection market is characterized by continuous development aimed at maximizing treatment effectiveness, enhancing patient convenience, and increasing its clinical usefulness in schizophrenia management. These development strides are indicative of the ongoing work to improve the lives of people who live with this disease.
Regulatory Approvals for Extended-Acting Formulations: Recent regulatory approvals of paliperidone palmitate formulations for three-month and six-month durations across different regions are a major step in the direction of minimizing the frequency of injections and maximizing patient adherence.
Post-Authorization Safety Studies: Ongoing post-authorization safety studies are giving important insights into the long-term safety and tolerability of various paliperidone palmitate formulations in various populations of patients.
Pharmacoeconomic Analyses: Greater availability of pharmacoeconomic data is assisting in the demonstration of the value of long-acting paliperidone palmitate injections in terms of fewer relapses, hospitalizations, and total healthcare costs.
Development of Better Injection Devices: Initiatives are in place to create more comfortable and less painful injection devices for delivering paliperidone palmitate, improving the patient experience.
Investigation of Use in Bipolar Disorder: Though largely indicated for schizophrenia, studies are examining the possible use of paliperidone palmitate in treating some symptoms of bipolar disorder, thus possibly broadening its uses.
These major advancements are having a considerable influence on the paliperidone palmitate therapeutic injection market by providing more convenient and possibly cost-saving treatment, increased knowledge of long-term safety, better administration experience, and investigation of new therapeutic applications. The emphasis on longer-acting products, safety information, economic benefit, injection equipment, and wider indications is reinforcing its position in psychiatric treatment.
Strategic Growth Opportunities in the Paliperidone Palmitate Therapeutic Injection Market
Paliperidone palmitate therapeutic injection offers numerous strategic market opportunities with targeted growth prospects on selective patient bases and streamlined treatments of schizophrenia. A marketing strategic approach toward treatment aimed at treating the unsatisfied market demands with high expectations toward good results could prove market increasing.
Early Intervention in First-Episode Psychosis: Proactive treatment with long-acting paliperidone palmitate in patients with their first episode of psychosis to enhance adherence and long-term results, possibly averting relapse and functional deterioration.
Treatment of Patients with Poor Adherence: Treating patients with a history of poor compliance with oral antipsychotics with long-acting paliperidone palmitate injections to provide stable medication delivery and minimize the risk of relapse.
Simplified Maintenance Therapy: Using ultra-long-acting formulations (three-month and six-month) in stable patients to minimize the number of clinic visits and enhance their quality of life and convenience.
Bridging the Gap in Transition of Care: Using paliperidone palmitate injections during care transitions, e.g., hospital discharge, to maintain continuity of treatment and avoid relapse.
Treating Specific Subgroups of Schizophrenia: Evaluating the efficacy and safety of paliperidone palmitate in specific subgroups of schizophrenia patients, including those with predominantly negative symptoms or comorbid substance use disorders.
These application-based strategic growth opportunities are shaping the paliperidone palmitate therapeutic injection market by revealing its promise to enhance outcomes at many stages of schizophrenia treatment and among certain patient populations. Targeting early treatment, adherence issues, streamlined maintenance, transitions of care, and particular subgroups can fuel greater adoption and the clinical worth of this therapy.
Paliperidone Palmitate Therapeutic Injection Market Driver and Challenges
The paliperidone palmitate therapeutic injection market is driven by a mix of clinical requirements, pharmacological benefits, economic factors, and healthcare system influences, which serve as both key drivers for its uptake and key challenges that stakeholders need to overcome for long-term growth. It is important to comprehend these dynamics to achieve market success.
The factors responsible for driving the paliperidone palmitate therapeutic injection market include:
1. Enhanced Adherence to Schizophrenia Therapy: The major incentive for paliperidone palmitate injections is that they help address the key issue of non-adherence with medications by schizophrenia patients, resulting in enhanced symptom management and lower relapse rates.
2. Preparable Pharmacokinetics and Steady State: Long-acting injectables have reproducible drug levels and steady-state release, allowing consistent therapeutic effects and perhaps lessened risk of side effects related to varying oral drug levels.
3. Lower Burden of Daily Oral Medication: Less frequent injections versus daily oral medication dramatically lower the treatment burden and enhance convenience for patients and caregivers.
4. Increased Awareness of the Advantages of LAIs: Enhanced awareness among psychiatrists and patients regarding the benefits of long-acting injectable antipsychotics in enhancing long-term outcomes is propelling their use.
5. Supportive Clinical Guidelines and Reimbursement Policies: Clinical practice guidelines that support LAIs for specific patient groups and positive reimbursement policies in some markets enable market access and expansion.
Challenges in the paliperidone palmitate therapeutic injection market are:
1. Increased Cost Compared to Oral Drugs: Paliperidone palmitate injections tend to be more expensive per dose than generic oral antipsychotics, which can limit access, especially in cost-containment healthcare systems.
2. Need for Trained Health Professionals for Administration: Intramuscular injections must be administered by trained health professionals, which may restrict access where there are resource limitations.
3. Patient Acceptance and Stigma Relating to Injections: Patient acceptance of receiving injections may be low due to discomfort, anxiety, or stigma related to the use of injectable medication for mental illness.
The significant drivers for enhanced adherence, consistent pharmacokinetics, low treatment burden, increased LAI awareness of benefits, and concurring guidelines are driving the expansion of the paliperidone palmitate therapeutic injection market. Yet, issues of increased cost, professional administration necessity, and patient acceptance necessitate continued efforts in cost containment, training, patient education, and stigma reduction for greater and more equitable availability of this useful treatment for schizophrenia.
List of Paliperidone Palmitate Therapeutic Injection Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, paliperidone palmitate therapeutic injection companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the paliperidone palmitate therapeutic injection companies profiled in this report include:
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Sun Pharmaceutical
Cipla
Hikma Pharmaceuticals
Qilu Pharmaceutical
Paliperidone Palmitate Therapeutic Injection Market by Segment
The study includes a forecast for the global paliperidone palmitate therapeutic injection market by type, application, and region.
Paliperidone Palmitate Therapeutic Injection Market by Type [Value from 2019 to 2031]:
Monthly Dosage Form
Quarterly Dosage Form
Paliperidone Palmitate Therapeutic Injection Market by Application [Value from 2019 to 2031]:
General Hospital
Specialized Hospital
Others
Paliperidone Palmitate Therapeutic Injection Market by Region [Value from 2019 to 2031]:
North America
Europe
Asia Pacific
The Rest of the World
Country Wise Outlook for the Paliperidone Palmitate Therapeutic Injection Market
The paliperidone palmitate therapeutic injection market is a major therapeutic area in the long-acting injectable antipsychotic treatment of schizophrenia. Recent trends are centered around longer-acting formulations to promote better patient compliance, injection technology advancements for more convenient administration, and new indications to treat an increasing patient base. Regulatory clearance and market access strategies continue to influence its progress in various geographic regions.
United States: The US market is the most significant consumer of paliperidone palmitate injections, with an emphasis on the once-monthly and longer-acting (three-month and six-month) products. Recent trends include continued investigation of even longer-acting products and initiatives to increase access and mitigate the cost of frequent clinic visits for schizophrenia patients.
China: China's market for paliperidone palmitate injections is expanding, fueled by the rising awareness of schizophrenia and the convenience of long-acting treatments for compliance. The latest developments include regulatory approvals for longer-acting formulations and attempts to add these drugs to national reimbursement lists in order to enhance affordability and accessibility.
Germany: Germany's healthcare system has good access to long-acting injectable antipsychotics such as paliperidone palmitate. Recent trends center on maximizing treatment pathways, including the utilization of longer-acting formulations to increase patient stability and minimize relapse rates. Real-world evidence studies are helping inform long-term outcomes.
India: The market for paliperidone palmitate injections in India is growing, though affordability is still a major factor. Recent trends have seen more affordable generic versions available and growing awareness among psychiatrists regarding the advantages of long-acting injectables in enhancing patient adherence in schizophrenia.
Japan: Japan's paliperidone palmitate injection market focuses on the health and compliance of patients. New developments involve authorization and use of longer-acting products to enable less-frequent visits to the clinic. Patient support programs are also emphasized to enhance treatment efficacy and quality of life.
Features of the Global Paliperidone Palmitate Therapeutic Injection Market
Market Size Estimates: Paliperidone palmitate therapeutic injection market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Paliperidone palmitate therapeutic injection market size by type, application, and region in terms of value ($B).
Regional Analysis: Paliperidone palmitate therapeutic injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the paliperidone palmitate therapeutic injection market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the paliperidone palmitate therapeutic injection market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the paliperidone palmitate therapeutic injection market by type (monthly dosage form and quarterly dosage form), application (general hospital, specialized hospital, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Paliperidone Palmitate Therapeutic Injection Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Monthly Dosage Form: Trends and Forecast (2019-2031)
4.4 Quarterly Dosage Form: Trends and Forecast (2019-2031)
5. Global Paliperidone Palmitate Therapeutic Injection Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 General Hospital: Trends and Forecast (2019-2031)
5.4 Specialized Hospital: Trends and Forecast (2019-2031)
5.5 Others: Trends and Forecast (2019-2031)
6. Regional Analysis
6.1 Overview
6.2 Global Paliperidone Palmitate Therapeutic Injection Market by Region
7. North American Paliperidone Palmitate Therapeutic Injection Market
7.1 Overview
7.2 North American Paliperidone Palmitate Therapeutic Injection Market by Type
7.3 North American Paliperidone Palmitate Therapeutic Injection Market by Application
7.4 United States Paliperidone Palmitate Therapeutic Injection Market
